plerixafor has been researched along with Lymphoma, Non-Hodgkin in 72 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (19.44) | 29.6817 |
| 2010's | 58 (80.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonifazi, F; Bosi, A; Cascavilla, N; Cellini, C; Lanza, F; Laszlo, D; Martino, M; Musto, P; Pezzi, A; Saraceni, F; Tani, M; Zuffa, E | 1 |
| Azar, N; Chabannon, C; Farina, L; Glaß, B; Hübel, K; Karlin, L; Kron, A; Kron, F; Le Gouill, S; Milkovich, G; Mohty, M; Noppeney, R; Ostermann, H | 1 |
| Bolwell, B; Cheverton, PD; DiPersio, JF; Horwitz, ME; Kaufman, JL; Maziarz, RT; McCarty, JM; Micallef, IN; Nademanee, AP; Stadtmauer, EA; Stiff, PJ; Struijs, M; Vargo, R | 1 |
| Glaß, B; Hübel, K; Kron, A; Kron, F; Milkovich, G; Mohty, M; Noppeney, R; Ostermann, H | 1 |
| Culligan, DJ; Dong, B; Hay, AE; Lawrie, A; Robinson, N | 1 |
| Carlo-Stella, C; Corradini, P; Dodero, A; Farina, L; Guidetti, A; Longoni, P; Montefusco, V; Ravagnani, F; Spina, F | 1 |
| Alousi, A; Anderlini, P; Champlin, R; Ciurea, S; de Lima, M; Hosing, C; Kebriaei, P; Khouri, I; Nieto, Y; Popat, U; Qazilbash, M; Rondon, G; Smith, VR | 1 |
| Bilgin, YM; Croockewit, A; de Greef, GE; Gahar, RR; Visser, O | 1 |
| Bolwell, BJ; DiPersio, JF; Marulkar, S; Maziarz, RT; Micallef, IN; Nademanee, AP; Partisano, AM; Stadtmauer, EA; Stiff, PJ | 1 |
| Jantunen, E; Kuittinen, O; Kuittinen, T; Kuitunen, H; Kutila, A; Lehtonen, P; Mäntymaa, P; Mikkola, M; Nihtinen, A; Nousiainen, T; Rimpiläinen, J; Varmavuo, V; Vasala, K | 1 |
| Isola, LM; Miller, LK; Shi, PA | 1 |
| Bensinger, W; Copelan, E; Costa, L; Devine, S; Dipersio, J; Giralt, S; Hosing, C; Leather, H; Maziarz, R; McCarty, J; Negrin, R; Pazzalia, A; Petersen, FB; Rondelli, D; Schriber, J; Shaughnessy, P; Snyder, E; Soiffer, R | 1 |
| Carlo-Stella, C; Corradini, P; Farina, L; Guidetti, A; Longoni, P; Ravagnani, F; Roncari, L; Spina, F | 1 |
| Bonferroni, M; Borra, A; Castellino, C; Celeghini, I; Di Marco, C; Fiore, F; Gallamini, A; Ghiglia, A; Grasso, M; Marenchino, D; Mattei, D; Mordini, N; Rapezzi, D; Sorasio, R; Strola, G | 1 |
| Gardellini, A; Lanza, F; Laszlo, D; Martino, M | 1 |
| Costa, LJ; Dermer, SJ; Kumar, S; Stowell, SA | 1 |
| Arabi, A; Bekadja, MA; Bouhass, R; Brahimi, M; Osmani, S; Talhi, S; Yafour, N | 1 |
| Beckers, EA; Bilgin, YM; Croockewit, AJ; de Greef, GE; Huisman, C; Kramer, EP; Netelenbos, T; te Boome, LC; Visser, O; Ypma, PF | 1 |
| Jantunen, E; Kuittinen, T; Lehtonen, P; Mäntymaa, P; Nihtinen, A; Nousiainen, T; Partanen, A; Pelkonen, J; Penttilä, K; Pyörälä, M; Ropponen, A; Silvennoinen, R; Valtola, J; Varmavuo, V; Vasala, K | 1 |
| Bao, M; Guan, Y; Guo, R; Li, X; Wang, Y; Wu, A; Xie, F; Yue, Y; Zhang, C | 1 |
| Danylesko, I; Nagler, A; Sareli, R; Shem-Tov, N; Shimoni, A; Varda-Bloom, N; Yerushalmi, R | 1 |
| Engert, A; Hartmann, T; Hübel, K; Monsef, I; Skoetz, N | 1 |
| Motalkina, MS | 1 |
| Craig, MD; Cumpston, A; D'Souza, A; Dhakal, B; Eastwood, D; Esselman, J; Fenske, TS; Hamadani, M; Hari, P; Kanate, AS; Pasquini, MC; Shillingburg, A; Veltri, LW; Watkins, K | 1 |
| Jantunen, E; Valtola, J; Varmavuo, V | 1 |
| Calandra, G; MacFarland, R; Smith, C; Stewart, DA | 1 |
| De Clercq, E | 1 |
| Badel, K; Calandra, G; Magalhaes-Silverman, M; McCarthy, P; Micallef, I; Stiff, P; Territo, M; Weisdorf, D | 1 |
| DiPersio, JF; Kirkpatrick, P; Uy, GL; Yasothan, U | 1 |
| Wagstaff, AJ | 1 |
| Badel, K; Bensinger, WI; Bridger, G; Calandra, G; Dehner, C; Dugan, MJ; Gibney, C; Liesveld, J; Maziarz, RT; Nademanee, A | 1 |
| Badel, K; Calandra, G; Ehninger, G; Fruehauf, S; Goldschmidt, H; Ho, AD; Hübel, K; Moos, M; Müller, S; Topaly, J | 1 |
| Bolwell, BJ; Bridger, G; Calandra, G; DiPersio, JF; Jacobsen, E; Maziarz, RT; McCarty, J; Micallef, IN; Nademanee, A; Stiff, PJ | 1 |
| Gaarsdal, E; Hansen, PB | 1 |
| Bridger, G; Calandra, G; DiPersio, JF; Maziarz, RT; McCarty, JM; Micallef, IN; Stiff, PJ | 1 |
| Fesler, MJ; Kudva, G; Petruska, PJ | 1 |
| Choi, HY; Yong, CS; Yoo, BK | 1 |
| Jantunen, E; Kuittinen, T; Mahlamäki, E; Nousiainen, T; Penttilä, K; Pyörälä, M | 1 |
| Gatesman, ML; Kessans, MR; Kockler, DR | 1 |
| Booth, B; Brave, M; Ching Lin, S; Farrell, A; Fourie, J; He, K; Justice, R; Lee, SL; Ocheltree, T; Pazdur, R; Pope Miksinski, S; Saber, H; Tornoe, C; Yuan, W | 1 |
| Silva, M; Steinberg, M | 1 |
| Basak, GW; Dabrowska-Iwanicka, A; Dybko, J; Hawrylecka, D; Kisiel, E; Knopinska-Posluszny, W; Matuszak, M; Rzepecki, P; Szmigielska-Kaplon, A; Urbaniak-Kujda, D; Werkun, J; Wiktor-Jedrzejczak, W; Wroblewska, W; Zielinska, P | 1 |
| Albert, MH; Basara, N; Beier, R; Bogner, C; Christopeit, M; Dressler, S; Ebinger, M; Fresen, MM; Frickhofen, N; Galm, O; Hartwig, R; Heits, F; Hertenstein, B; Hübel, K; Kiehl, M; Kröger, N; Lange, F; Liebler, S; Lordick, F; Rösler, W; Salwender, H; Theurich, S; von Lilienfeld-Toal, M; Wehler, D; Weidmann, E; Weigelt, C; Zander, AR | 1 |
| Damon, LE | 1 |
| Bolwell, BJ; Bridger, G; DiPersio, JF; Hsu, FJ; Marulkar, S; Maziarz, RT; Micallef, I; Nademanee, AP; Stadtmauer, EA; Stiff, PJ | 1 |
| Jantunen, E; Kuittinen, T; Mahlamäki, E; Mäntymaa, P; Nousiainen, T; Pyörälä, M | 1 |
| Basak, GW; Basic-Kinda, S; Cegledi, A; Giebel, S; Hübel, K; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Reti, M; Wiktor-Jedrzejczak, W | 1 |
| Basak, GW; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Lanza, F; Lemoli, R; Mikala, G; Mohty, M; Selleslag, D; Wiktor-Jedrzejczak, W; Worel, N | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, R; Malard, F; Mikala, G; Mohty, M; Selleslag, D; Worel, N | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Fresen, MM; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, RM; Mikala, G; Mohty, M; Selleslag, D; Worel, N | 1 |
| Kaufman, J; Mahaseth, H | 1 |
| Jantunen, E; Juutilainen, A; Kuittinen, T; Mahlamäki, E; Mäntymaa, P; Nousiainen, T; Varmavuo, V | 1 |
| Jantunen, E; Kuittinen, T; Mäntymaa, P; Nousiainen, T; Varmavuo, V | 2 |
| Carson, KR; DiPersio, JF; Gregory, M; Kymes, SM; Lambert, DL; Pusic, I | 1 |
| Jantunen, E; Kuittinen, T; Mäntymaa, P; Nousiainen, T; Valonen, P; Varmavuo, V | 1 |
| Ball, ED; Belew, H; Helmons, PJ; Lane, JR; Lor, KW | 1 |
| Calandra, G; Gandhi, PJ; Jacobsen, ED; Micallef, IN; Shaughnessy, P; Uberti, J; van Rhee, F | 1 |
| Devine, SM | 1 |
| Ansell, SM; Buadi, F; Dingli, D; Dispenzieri, A; Gastineau, DA; Gertz, MA; Hayman, SR; Hogan, WJ; Inwards, DJ; Johnston, PB; Kumar, S; Lacy, MQ; Litzow, MR; Micallef, IN; Porrata, LF; Sinha, S; Winters, JL; Wolf, R | 1 |
| Carlson, K; Chabannon, C; Douglas, K; Ho, AD; Milone, G; Mohty, M; Ossenkoppele, GJ; Pareja, MO; Russell, N; Shaheen, D; Whitaker, N; Willemsen, A | 1 |
| Amico, I; Ancora, F; Bartolozzi, B; Bosi, A; Guidi, S; Iacopino, P; Irrera, G; La Fauci, A; Leotta, S; Martino, M; Milone, G; Nozzoli, C; Poidomani, M; Saccardi, R; Spadaro, A; Tripepi, G | 1 |
| Armistead, PM; Brown, PM; Coghill, JM; Essenmacher, A; Gabriel, DA; Goyal, R; Irons, R; Rao, KV; Sarantopoulos, S; Serody, JS; Sharf, A; Shea, TC; Whitley, J; Wood, WA | 1 |
| Artz, A; Ball, ED; Berryman, R; Devine, S; Dugan, M; Hsu, FJ; Jacobsen, E; Johns, D; Joyce, R; Maziarz, RT; McCarty, J; McSweeney, P; Micallef, I; Shaughnessy, P; Stiff, P; Uberti, J; Vose, J | 1 |
| Angell, J; Bolwell, BJ; Calandra, G; Dipersio, JF; Maziarz, RT; Micallef, IN; Nademanee, AP; Stiff, PJ | 1 |
| Badel, K; Calandra, G; Devine, SM; DiPersio, JF; Flomenberg, N; Liesveld, J; Vesole, DH; Weisdorf, D | 1 |
| Aglietta, M; Carnevale Schianca, F; Cavalloni, G; Grignani, G; Perissinotto, E | 1 |
| Ansell, SA; Gastineau, DA; Holtan, SG; Inwards, DJ; Johnston, PB; Markovic, SN; Micallef, IN; Padley, DJ; Porrata, LF | 1 |
| Akay, C; Badel, K; Calandra, G; Freytes, CO; Gazitt, Y | 1 |
11 review(s) available for plerixafor and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.
Topics: Benzylamines; Cyclams; Filgrastim; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Polyethylene Glycols; Recombinant Proteins; Survival Analysis; Transplantation, Autologous | 2014 |
Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
Topics: Benzylamines; Cyclams; Early Termination of Clinical Trials; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; Randomized Controlled Trials as Topic; Time Factors; Transplantation, Autologous | 2015 |
Plerixafor injection: a hematopoietic stem cell mobilizer in non-Hodgkin lymphoma and multiple myeloma.
Topics: Antigens, CD34; Benzylamines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Premedication; Treatment Outcome | 2016 |
The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil).
Topics: Amino Acid Sequence; Anti-HIV Agents; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; HIV; Humans; Lymphoma, Non-Hodgkin; Molecular Sequence Data; Multiple Myeloma; Protein Conformation; Receptors, CXCR4; Virus Internalization | 2009 |
Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma.
Topics: Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Infusions, Subcutaneous; Lymphoma, Non-Hodgkin; Multiple Myeloma; Receptors, CXCR4 | 2009 |
[Mobilisation of haematopoietic stem cells with plerixafor--secondary publication].
Topics: Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma | 2009 |
Plerixafor for stem cell mobilization in patients with non-Hodgkin's lymphoma and multiple myeloma.
Topics: Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation | 2010 |
Plerixafor: a peripheral blood stem cell mobilizer.
Topics: Animals; Benzylamines; Bone Marrow; Chemokine CXCL12; Contraindications; Cyclams; Drug Interactions; Drug Therapy, Combination; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Off-Label Use; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Salvage Therapy | 2010 |
Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Topics: Animals; Antineoplastic Agents; Benzylamines; Cyclams; Cyclophosphamide; Economics, Pharmaceutical; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Receptors, CXCR4 | 2010 |
Mobilization of hematopoietic stem cells into the peripheral blood.
Topics: Animals; Anti-HIV Agents; Benzylamines; Bone Marrow; Chemokine CXCL12; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Mice; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4 | 2009 |
Optimizing stem cell collection through CXCR4 antagonists.
Topics: Animals; Benzylamines; Clinical Trials, Phase III as Topic; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Randomized Controlled Trials as Topic; Receptors, CXCR4 | 2012 |
25 trial(s) available for plerixafor and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report.
Topics: Adolescent; Adult; Aged; Benzylamines; Child; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Longitudinal Studies; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Survival Analysis; Transplantation, Autologous; Young Adult | 2018 |
Plerixafor in non-Hodgkin's lymphoma patients: a German analysis of time, effort and costs.
Topics: Adult; Aged; Benzylamines; Blood Component Removal; Costs and Cost Analysis; Cyclams; Female; Germany; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Time Factors | 2019 |
Use of Plerixafor in patients that show failure of peripheral blood stem cell mobilization with G-CSF. Experience of three Dutch centers.
Topics: Anti-HIV Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous | 2013 |
Peripheral blood CD34+ percentage at hematological recovery after chemotherapy is a good early predictor of harvest: a single-center experience.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Biomarkers; Cyclams; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Time Factors; Transplantation, Autologous | 2014 |
Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.
Topics: Adult; Aged; Anti-HIV Agents; Autografts; Benzylamines; Cyclams; Disease-Free Survival; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukocytes; Lymphoma, Non-Hodgkin; Male; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Survival Rate | 2015 |
Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study.
Topics: Adult; Aged; Anti-HIV Agents; Autografts; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Pilot Projects; Receptors, CXCR4 | 2016 |
Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Pharmacokinetics; Receptors, CXCR4; Transplantation, Autologous | 2009 |
Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cell Count; Cyclams; Drug Therapy, Combination; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Receptors, CXCR4 | 2009 |
Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization.
Topics: Adult; Aged; Antigens, CD34; Antiviral Agents; Benzylamines; Blood Component Removal; Combined Modality Therapy; Cyclams; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Pilot Projects | 2010 |
Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Cell Count; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Polymerase Chain Reaction; Treatment Outcome | 2010 |
Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for
Topics: Adult; Aged; Benzylamines; Cyclams; Diarrhea; Double-Blind Method; Female; Granulocyte Colony-Stimulating Factor; Headache; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Infusions, Subcutaneous; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prospective Studies; Transplantation, Autologous; Treatment Outcome; Young Adult | 2009 |
Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol.
Topics: Benzylamines; Blood Component Removal; Combined Modality Therapy; Cyclams; Double-Blind Method; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged | 2009 |
Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
Topics: Adolescent; Adult; Aged; Benzylamines; Blood Component Removal; Child; Child, Preschool; Combined Modality Therapy; Compassionate Use Trials; Cyclams; Female; Germany; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Young Adult | 2011 |
Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
Topics: Antigens, CD34; Benzylamines; Blood Platelets; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Platelet Count; Survival Analysis; Transplantation, Autologous | 2011 |
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Child; Cyclams; Europe; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2011 |
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Compassionate Use Trials; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Vidarabine | 2012 |
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Benzylamines; Blood Component Removal; Child; Cyclams; European Union; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Transplantation, Homologous | 2012 |
Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft co
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous | 2012 |
Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
Topics: Adult; Aged; Algorithms; Benzylamines; Case-Control Studies; Costs and Cost Analysis; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Plasmacytoma; Risk Factors; Time Factors; Transplantation, Autologous | 2013 |
Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
Topics: Adult; Aged; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Treatment Outcome | 2013 |
Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.
Topics: Adult; Aged; Anti-HIV Agents; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Time Factors; Transplantation, Autologous; United States | 2013 |
Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; CD4 Lymphocyte Count; Cyclams; Double-Blind Method; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Middle Aged; Placebos; Transplantation, Autologous | 2013 |
Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cyclams; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Receptors, CXCR4; Statistics, Nonparametric | 2004 |
AMD3100 affects autograft lymphocyte collection and progression-free survival after autologous stem cell transplantation in non-Hodgkin lymphoma.
Topics: Adult; Aged; Benzylamines; Cyclams; Disease-Free Survival; Female; Heterocyclic Compounds; Humans; Lymphocyte Count; Lymphocytes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2007 |
Improved mobilization of peripheral blood CD34+ cells and dendritic cells by AMD3100 plus granulocyte-colony-stimulating factor in non-Hodgkin's lymphoma patients.
Topics: Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Benzylamines; Cyclams; Dendritic Cells; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Neutrophils; Patient Selection; Receptors, CXCR4; Recurrence; Tissue Preservation; Transplantation Conditioning; Treatment Outcome | 2007 |
36 other study(ies) available for plerixafor and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity-score weighted multicenter approach.
Topics: Benzylamines; Biosimilar Pharmaceuticals; Blood Cell Count; Cyclams; Filgrastim; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Propensity Score; Retrospective Studies | 2017 |
Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Salvage Therapy; Time Factors; Treatment Failure | 2018 |
A retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly.
Topics: Antigens, CD34; Benzylamines; Blood Component Removal; Body Weight; Cost-Benefit Analysis; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; Regression Analysis; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2013 |
Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor.
Topics: Adult; Aged; Algorithms; Antigens, CD34; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Cyclophosphamide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukocyte Count; Leukocytes, Mononuclear; Logistic Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Multivariate Analysis; Time Factors; Transplantation, Autologous; Young Adult | 2014 |
Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cell Count; Cyclams; Drug Therapy, Combination; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Time Factors; Transplantation, Autologous; Treatment Outcome | 2013 |
Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Cell Count; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclams; Double-Blind Method; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Neutropenia; Pain; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Young Adult | 2013 |
Engraftment and outcome after autologous stem cell transplantation in plerixafor-mobilized non-Hodgkin's lymphoma patients.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cell Separation; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Receptors, CXCR4; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2014 |
Prospective study of mobilization kinetics up to 18 hours after late-afternoon dosing of plerixafor.
Topics: Antigens, CD34; Benzylamines; Cohort Studies; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Kinetics; Leukapheresis; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Receptors, CXCR4; Time Factors | 2014 |
Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF.
Topics: Adult; Aged; Algorithms; Antigens, CD34; Antineoplastic Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged | 2014 |
Plerixafor: what we still have to learn.
Topics: Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Obesity; Overweight; Patient Selection; Transplantation, Autologous | 2015 |
Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.
Topics: Benzylamines; Cyclams; Cyclophosphamide; Data Collection; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Lymphoma, Non-Hodgkin; Multiple Myeloma; Practice Patterns, Physicians'; Thalidomide | 2015 |
Plerixafor in the treatment of progenitor cell mobilization failure: First experience in Algeria.
Topics: Adult; Algeria; Antigens, CD34; Benzylamines; Cyclams; Female; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Receptors, CXCR4; Stem Cell Transplantation; Young Adult | 2015 |
Evaluation of Dutch guideline for just-in-time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte-colony-stimulating factor.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Netherlands; Retrospective Studies | 2015 |
Plerixafor may treat intractable post-herpetic neuralgia.
Topics: Benzylamines; Bone Marrow Cells; Cell Movement; Cyclams; Ganglion Cysts; Herpes Zoster; Heterocyclic Compounds; Humans; Inflammation; Lymphoma, Non-Hodgkin; Models, Theoretical; Multiple Myeloma; Neuralgia; Neuralgia, Postherpetic; Neurons; Spinal Cord; Stem Cell Transplantation; Stem Cells; United States | 2015 |
[Combination of pegfilgrastim and plerixafor as an effective regimen of hematopoietic stem cells mobilization in cancer patients: own experience].
Topics: Adult; Aged; Antineoplastic Agents; Benzylamines; Blood Component Removal; Cyclams; Cyclophosphamide; Dexamethasone; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Recombinant Proteins | 2015 |
Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Transfusion; Carboplatin; Cyclams; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Young Adult | 2016 |
Plerixafor.
Topics: Animals; Benzylamines; Cyclams; Drug Approval; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Randomized Controlled Trials as Topic; Receptors, CXCR4 | 2009 |
Plerixafor and pegylated filgrastim: a case of safe and effective hematopoietic stem cell mobilization.
Topics: Benzylamines; Cyclams; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Recombinant Proteins; Remission Induction | 2010 |
Plerixafor (Mozobil).
Topics: Antineoplastic Agents; Benzylamines; Combined Modality Therapy; Cyclams; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Receptors, CXCR4; Transplantation, Autologous | 2010 |
Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients.
Topics: Aged; Antineoplastic Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma | 2011 |
FDA review summary: Mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Clinical Trials as Topic; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Placebos; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Receptors, CXCR4; United States; United States Food and Drug Administration | 2010 |
Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.
Topics: Adult; Aged; Antigens, CD34; Benzylamines; Cohort Studies; Compassionate Use Trials; Cyclams; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Poland; Receptors, CXCR4; Retrospective Studies; Transplantation, Autologous; Young Adult | 2011 |
Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Female; Filgrastim; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Polyethylene Glycols; Receptors, CXCR4; Recombinant Proteins; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome | 2011 |
Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late.
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Benzylamines; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF.
Topics: Adult; Aged; Aged, 80 and over; Benzylamines; Body Mass Index; Contraindications; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Obesity; Overweight; Retrospective Studies; Thinness; Young Adult | 2012 |
Kinetics of blood CD34(+) cells after chemotherapy plus G-CSF in poor mobilizers: implications for pre-emptive plerixafor use.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Chemoprevention; Cyclams; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Kinetics; Leukocyte Count; Leukocytes; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Prognosis; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure | 2012 |
Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Component Removal; Combined Modality Therapy; Cyclams; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Leukocyte Count; Lymphocyte Subsets; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Receptors, CXCR4; Retrospective Studies; Rituximab; Stem Cell Transplantation; Transplantation, Autologous; Vincristine | 2012 |
Economic evaluation of plerixafor for stem cell mobilization.
Topics: Benzylamines; Costs and Cost Analysis; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Markov Chains; Outcome Assessment, Health Care | 2012 |
Blood graft composition after plerixafor injection in patients with NHL.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cyclams; Female; Flow Cytometry; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Killer Cells, Natural; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; T-Lymphocytes; Transplantation, Autologous | 2012 |
Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Topics: Academic Medical Centers; Adult; Aged; Antigens, CD34; Benzylamines; Blood Component Removal; Cyclams; Cyclophosphamide; Drug Therapy, Combination; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Retrospective Studies; Salvage Therapy; Transplantation, Autologous | 2012 |
G-CSF plus plerixafor (Mozobil) to mobilize hematopoietic stem cells in patients with thrombocytopenia or leukopenia prior to auto-SCT.
Topics: Benzylamines; Blood Component Removal; Cyclams; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Leukocyte Count; Leukopenia; Lymphoma, Non-Hodgkin; Multiple Myeloma; Platelet Count; Retrospective Studies; Thrombocytopenia | 2013 |
Toward a more rational policy for autologous hematopoietic stem cell mobilization.
Topics: Antigens, CD34; Benzylamines; Clinical Trials, Phase III as Topic; Cyclams; Drug Combinations; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Immunologic Factors; Lymphoma, Non-Hodgkin; Multiple Myeloma; Receptors, CXCR4; Transplantation, Autologous | 2012 |
Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding "on demand" use of plerixafor.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Benzylamines; Cyclams; Cyclophosphamide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Hodgkin Disease; Humans; Leukocyte Count; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Transplantation, Autologous | 2013 |
Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT.
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Autografts; Benzylamines; Costs and Cost Analysis; Cyclams; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged | 2013 |
Clinical use of AMD3100 to mobilize CD34+ cells in patients affected by non-Hodgkin's lymphoma or multiple myeloma.
Topics: Antigens, CD34; Benzylamines; Cyclams; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Multiple Myeloma; Receptors, CXCR4 | 2005 |
Molecule of the month. Plerixafor hydrochloride.
Topics: Anti-HIV Agents; Benzylamines; Clinical Trials as Topic; Cyclams; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Molecular Structure; Multiple Myeloma; Receptors, CXCR4 | 2007 |